Compare Amgen, Inc. (AMGN) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs United States Natural Gas Fund — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while United States Natural Gas Fund trades at $10.45. The key difference: Amgen, Inc. pays a 2.77% dividend while United States Natural Gas Fund pays none, and Amgen, Inc. is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| AMGN | UNG | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Commodities - Energy |
52-Week High | $388.16 | $16.90 |
52-Week Low | $271.18 | $10.15 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
UNG (United States Natural Gas Fund) trades at $10.60, down 2.12% amid bearish technical signals with 17 sell indicators versus 3 buy signals. The ETF faces headwinds from natural gas price volatility, though RSI levels near 30 suggest potential oversold conditions. Recent news highlights weather-driven demand fluctuations and structural challenges including contango effects that have historically eroded long-term returns.
Outlook remains cautious given the fund's tracking of futures contracts rather than company fundamentals. Key risks include weather dependency and LNG export volatility, while oversold technical conditions may offer short-term trading opportunities for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
